Pharmacogenomics: a reality or still a promise?
Pharmacogenomics: a reality or still a promise?
复制标题
药物基因组学：现实还是承诺？
DOI：
10.1016/j.lungcan.2006.09.014
复制
发表时间：
2006
期刊：
影响因子：
--
通讯作者：
Bepler,Gerold
中科院分区：
文献类型：
--
作者：
Bepler,Gerold
尽管近年来非小细胞肺癌(NSCLC)的治疗取得了显著的进展，但对于大多数患者来说，这种疾病仍然与预后不良有关。现代技术促进了对可能在疾病进展和患者治疗反应中发挥作用的特定遗传因素的识别，促使研究努力确定非小细胞肺癌预后的临床预测因素。最近的证据表明，药物基因组学方法的应用有可能极大地提高NSCLC患者某些亚群的存活率，这可能会深刻地影响用于进化这种恶性肿瘤治疗策略的决策过程。
Although notable progress has been made in the treatment of non-small-cell lung cancer (NSCLC) in recent years, this disease is still associated with a poor prognosis for most patients. Modern techniques have facilitated the identification of specific genetic factors that may play a role in disease progression and patient response to therapy, prompting research efforts to identify the clinical predictors of outcome for NSCLC. Recent evidence suggests that the application of a pharmacogenomic approach has the potential to greatly improve survival in certain subpopulations of patients with NSCLC, which could profoundly influence the decision-making process used in evolving treatment strategies for this malignancy.